<DOC>
	<DOCNO>NCT00537745</DOCNO>
	<brief_summary>The purpose study determine whether Vivitrol effective reduce attempt drive drinking among repeat drive intoxicate ( DWI ) offenders Ignition Interlock device .</brief_summary>
	<brief_title>Vivitrol Reducing Driving While Impaired Behavior Among Repeat Offenders</brief_title>
	<detailed_description>We propose conduct open label trial Vivitrol combination individual compliance enhancement therapy know Medication Management Therapy ( MMT ) adjunct Ignition Interlock management treatment DWI . Subjects recruit local Interlock provider . This program research collect pilot data study determine whether pharmacotherapy , previously recognize effective , successfully combine exist counsel treatment sanction person convict repeat DWI alcohol offense . We investigate extent combination sanction treatment significantly decrease attempt drive drinking among offender , whether effect persist follow discontinuation Vivitrol .</detailed_description>
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Inclusion Criteria Age â‰¥ 18 Capable understand comply protocol , sign informed consent document Been convict DWI offense , least one additional arrest DWI , enter ignition interlock program They must able participate 6 month outpatient study ; reside within onehour commute research site Women childbearing potential must negative pregnancy test , use contraceptive method , breastfeed Negative urine toxicological screen opiates screen randomization Has noncustodial stable residence telephone Exclusion Criteria Is pregnant and/or currently breastfeed Has clinically significant medical condition observe abnormality contraindicate Vivitrol treatment Is take excluded medication , include limited benzodiazepine , anticonvulsant , opiate , alcohol treatment medication Not stable current antidepressant , evidence less 3 month current dosage , plan discontinue , plan change dosage Has hospitalize medical detoxification within 30 day screen Has evidence severe kidney , heart , lung disease Has evidence severe hepatic disease ( evidence BUN &gt; 10 % ULN , AST , ALT &gt; 3x ULN , GGT &gt; 5x ULN randomization ) Known suspect hypersensitivity naltrexone and/or Vivitrol particular Current diagnosis symptom major depression , anxiety disorder , mania psychosis ( subject illness remission 3 month may include ) Opioid use within past 14 day and/or current recent ( within past year ) diagnosis dependence abuse opiates , benzodiazepine , cocaine . Current anticipate need prescribe opiate medication study period Medication naltrexone , disulfiram , acamprosate medication use treat alcoholism within past 30 day Impending incarceration know situation would preclude participation study Other nonalcohol Axis I substance dependence diagnosis past 12 month , exclude nicotine , marijuana , caffeine Has participate clinical trial pharmacological agent within 30 day screen Has find view principal investigator would compromise subject 's ability fulfill protocol visit schedule , and/or visit requirement would affect subject safety participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>